Literature DB >> 16432139

Developing therapeutics for the diseases of protein misfolding.

Barnaby C H May1, Cedric Govaerts, Fred E Cohen.   

Abstract

Our current structural and biologic understanding of the misfolding diseases has restricted the development of therapies that target these diseases at a molecular level. The prion diseases are illustrative of this group of misfolding disorders and provide a model system for therapeutic intervention. Strategies to inhibit the replication and accumulation of the prion protein are being developed and have entered animal and clinical studies. Due to the underlying molecular basis of this disease class, many of the therapeutic approaches used to target prion misfolding have parallels in other misfolding diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16432139     DOI: 10.1212/01.wnl.0000192309.26571.a7

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  1 in total

1.  Antiprion activity of cholesterol esterification modulators: a comparative study using ex vivo sheep fibroblasts and lymphocytes and mouse neuroblastoma cell lines.

Authors:  Alessandra Pani; Claudia Norfo; Claudia Abete; Claudia Mulas; Marirosa Putzolu; Sergio Laconi; Christina Doriana Orrù; M Dolores Cannas; Sarah Vascellari; Paolo La Colla; Sandra Dessì
Journal:  Antimicrob Agents Chemother       Date:  2007-08-20       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.